A bispecific antibody against IL-1β and IL-17A is beneficial for experimental rheumatoid arthritis

International Immunopharmacology

Volumn 14, Issue 4, 2012, Pages 770-778

  Qi, Jianying ^a   Kan, Fangming ^a   Ye, Xianlong ^a   Guo, Mo ^a   Zhang, Yu ^a   Ren, Guiping ^a   Li, Deshan ^a  

^a NORTHEAST AGRICULTURAL UNIVERSITY   (China)

Author keywords

Antibody; Bispecific antibody; IL 1 ; IL 17A; Rheumatoid arthritis (RA)

Indexed keywords

BISPECIFIC ANTIBODY; COLLAGEN TYPE 2; DEXAMETHASONE; GAMMA INTERFERON; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 6; INTERLEUKIN 8; MESSENGER RNA; SINGLE CHAIN BISPECIFIC ANTIBODY 1 17; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN BINDING; ARTICLE; BINDING AFFINITY; CELL PROLIFERATION; CONTROLLED STUDY; CROSS LINKING; DRUG POTENCY; GENE EXPRESSION; HISTOLOGY; HUMAN; HUMAN CELL; IMMUNIZATION; IN VITRO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SPLEEN CELL; SYNOVIUM; TREATMENT DURATION;

ANIMALS; ANTIBODIES; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; COLLAGEN; IMMUNIZATION; IMMUNOTHERAPY; INTERLEUKIN-17; INTERLEUKIN-1BETA; MICE;

EID: 84868564380     PISSN: 15675769     EISSN: 18781705     Source Type: Journal    
DOI: 10.1016/j.intimp.2012.10.005     Document Type: Article

References (61)

1. M. Feldmann, and R.N. Maini Anti-TNFα therapy of rheumatoid arthritis: what have we learned? Annu Rev Immunol 19 2001 163 196
2. J.G. Jeong, J.M. Kim, H. Cho, W. Hahn, S.S. Yu, and S. Kim Effects of IL-1beta on gene expression in human rheumatoid synovial fibroblasts Biochem Biophys Res Commun 324 2004 3 7
3. P.E. Lipsky, D.M. Van der Heijde, E.W. St Clair, D.E. Furst, F.C. Breedveld, and J.R. Kalden Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-tumor necrosis factor trial in heumatoid arthritis with concomitant therapy study group N Engl J Med 343 2000 1594 1602
4. S. Cohen, E. Hurd, J. Cush, M. Schiff, M.E. Weinblatt, and L.W. Moreland Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebocontrolled trial Arthritis Rheum 46 2002 614 624
5. K.A. Bush, K.M. Farmer, J.S. Walker, and B.W. Kirkham Reduction of joint inflammation and bone erosion in rat adjuvant arthritis by treatment with interleukin-17 receptor IgG1 Fc fusion protein Arthritis Rheum 46 2002 802 805
6. Chichao Cheng, Shijuan Chen, I.E. Adamopoulos, D. Nicole, H. Kyu, and V. Anna Anti-IL-17A therapy protects against bone erosion in experimental models of rheumatoid arthritis Autoimmunity 44 2011 243 252
7. F. Fossiez, O. Djossou, P. Chomarat, L. FloresRomo, S. Ait-Yahia, and C. Maat T-cell IL-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines J Exp Med 183 1996 2593
8. D.V. Jovanovic, J.A. DiBattista, J. Martel-Pelletier, F.C. Jolicoeur, Y. He, and M. Zhang IL-17 stimulates the production and expression of proinflammatory cytokines, IL-1β and TNF-α, by human macrophages J Immunol 160 1998 3513
9. T. Kasama, Y. Miwa, T. Isozaki, T. Odai, M. Adachi, and S.L. Kunkel Neutrophil-derived cytokines: potential therapeutic targets in inflammation Curr Drug Targets Inflamm Allergy 4 2005 273 279
10. Y. Mitani, A. Honda, and H.E. Jasin Polymorphonuclear leukocyte adhesion to articular cartilage is inhibited by cartilage surface macromolecules Rheumatol Int 20 2001 180 185
11. F.M. Brennan, and I.B. McInnes Evidence that cytokines play a role in rheumatoid arthritis J Clin Invest 118 2008 3537 3545
12. A.C. Issekutz, A. Meager, I. Otterness, and T.B. Issekutz The role of tumour necrosis factor-alpha and IL-1 in polymorphonuclear leucocyte and T lymphocyte recruitment to joint inflammation in adjuvant arthritis Clin Exp Immunol 97 1994 26 32
13. R.C. Borghaei, P.L. Rawlings Jr., and E. Mochan Interleukin-4 suppression of interleukin-1-nducied transcription of collagenase (MMP-1) and stromelysin 1 (MMP-3) in human sy novial fibroblasts Arthritis Rheum 41 8 1998 1398 1406
14. D. Meller, D.Q. Li, and S.C. Tseng Regulation of collagenase, stromelysin, and gelatinase B in human conjunctival and conjunctivochalasis fibroblasts by interleukin-1beta and tumor necrosis factor-alpha Invest Ophthalmol Vis Sci 41 10 2000 2922 2929
15. W. Hur, M.L. Cho, S.K. Yoon, and S.Y. Kim Adenoviral delivery of IL-1 receptor antagonist abrogates disease activity during the development of autoimmune arthritis in IL-1 receptor antagonist-deficient mice Immunol Lett 106 2006 154 162
16. C.A. Dinarello Therapeutic strategies to reduce IL-1 activity in treating local and systemic inflammation Curr Opin Pharmacol 4 4 2004 378 385
17. D.E. Furst Anakinra: review of recombinant human interleukin-I receptor antagonist in the treatment of rheumatoid arthritis Clin Ther 26 12 2004 1960 1975
18. R.M. Fleischmann, J. Schechtman, R. Bennett, M.L. Handel, G.-R. Burmester, and J. Tesser Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis: a large, international, multicenter, placebo-controlled trial Arthritis Rheum 48 4 2003 927 934
19. M.H. Schiff Role of interleukin 1 and interleukin 1 receptor antagonist in the mediation of rheumatoid arthritis Ann Rheum Dis 59 Suppl. 1 2000 i103 i108
20. J.G. Jeong, J.M. Kim, S.H. Ho, W. Hahn, S.S. Yu, and S. Kim Electrotransfer of human IL-1Ra into skeletal muscles reduces the incidence of murine collagen-induced arthritis J Gene Med 6 10 2004 1125 1133
21. D.M. Chang, S.K. Shyue, S.H. Liu, Y.T. Chen, C.Y. Yeh, and J.H. Lai Dual biological functions of an interleukin-1 receptor antagonist-interleukin-10 fusion protein and its suppressive effects on joint inflammation Immunology 112 4 2004 643 650
22. J.M. Kim, J.G. Jeong, S.H. Ho, W. Hahn, E.J. Park, and S. Kim Protection against collagen-induced arthritis by intramuscular gene therapy with an expression plasmid for the interleukin-1 receptor antagonist Gene Ther 10 18 2003 1543 1550
23. K. Inoue, K. Masuko-Hongo, M. Okamoto, and K. Nishioka Efficacy of daily compared to intermittent administration of IL-1Ra for protection against bone and cartilage destruction in collagen-challenged mice Clin Exp Rheumatol 21 1 2003 33 39
24. J. Zwerina, K. Redlich, G. Schett, and J.S. Smolen Pathogenesis of rheumatoid arthritis: targeting cytokines Ann NY Acad Sci 1051 2005 716 729
25. A.M. Zuurmond, A. Koudijs, B. Van El, and R.P. Doornbos Integration of efficacy, pharmacokinetic and safety assessment of interleukin-1 receptor antagonist in a preclinical model of arthritis Regul Toxicol Pharmacol 59 2011 461 470
26. E.H. Choy, and G.S. Panayi Cytokine pathways and joint inflammation in rheumatoid arthritis N Engl J Med 344 2001 907 916
27. M. Suzuki, T. Tetsuka, S. Yoshida, N. Watanabe, M. Kobayashi, and N. Matsui The role of p38 mitogen-activated protein kinase in IL-6 and IL-8 production from the TNF-alpha- or IL-1beta-stimulated rheumatoid synovial fibroblasts FEBS Lett 465 2000 23 27
28. A.I. Catrina, J. Lampa, S. Ernestam, E. af Klint, J. Bratt, and L. Klareskog Anti-tumour necrosis factor (TNF)-alpha therapy (etanercept) down-regulates serum matrix metalloproteinase (MMP)-3 and MMP-1 in rheumatoid arthritis Rheumatology (Oxford) 41 2002 484 489
29. S.R. Goldring Bone and joint destruction in rheumatoid arthritis: what is really happening? J Rheumatol Suppl 65 2002 44 48
30. K. Prowse, and H. Baumann Interleukin-1 and interleukin-6 stimulate acute-phase protein production in primary mouse hepatocytes J Leukoc Biol 45 1989 55 61
31. K. Ishihara, and T. Hirano IL-6 in autoimmune disease and chronic inflammatory proliferative disease Cytokine Growth Factor Rev 13 2002 357 368
32. T. Kishimoto Interleukin-6: discovery of a pleiotropic cytokine Arthritis Res Ther 8 2006 S2
33. C. Gabay Interleukin-6 and chronic inflammation Arthritis Res Ther 8 Suppl. 2 2006 S3
34. A. Houssiau Frédéric, J.-P. Devogelaer, Jo Van Damme, Nagant De Deuxchaisnes Charles, and J. Van Snick Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides Arthritis Rheum 31 1988 784 788
35. N. Nishimoto, K. Yoshizaki, N. Miyasaka, K. Yamamoto, S. Kawai, and T. Takeuchi Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial Arthritis Rheum 50 2004 1761 1769
36. R.N. Maini, P.C. Taylor, J. Szechinski, K. Pavelka, J. Broll, and G. Balint Randomised clinical trial of the IL-6 receptor antagonist, tocilizumab (MRA), in rheumatoid arthritis patients with an incomplete response to methotrexate in Europe (CHARISMA) Arthritis Rheum 54 9 2006 2817 2829
37. R.N. Maini, P.C. Taylor, J. Szechinski, K. Pavelka, J. Broll, and G. Balint Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate Arthritis Rheum 54 2006 2817 2829
38. J.S. Smolen, A. Beaulieu, A. Rubbert-Roth, C. Ramos-Remus, J. Rovensky, and E. Alecock Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial Lancet 371 2008 987 997
39. J.A. Jazayeri, G.J. Carroll, and A.B. Vernallis Interleukin-6 subfamily cytokines and rheumatoid arthritis: role of antagonists Int Immunopharmacol 10 2010 1 8
40. Fernando Q. Cunha, and Sergio H. Ferreira IL-17 mediates articular hypernociception in antigen-induced arthritis in mice Pain 148 2010 247 256
41. M.J. Ruddy, F. Shen, J.B. Smith, A. Sharma, and S.L. Gaffen Interleukin-17 regulates expression of the CXC chemokine LIX/CXCL5 in osteoblasts: implications for inflammation and neutrophil recruitment J Leukoc Biol 76 2004 135 144
42. M.J. Ruddy, G.C. Wong, X.K. Liu, H. Yamamoto, S. Kasayama, and K.L. Kirkwood Functional cooperation between interleukin-17 and tumor necrosis factor-alpha is mediated by CCAAT/enhancer-binding protein family members J Biol Chem 279 2004 2559 2567
43. J. Witowski, K. Ksiazek, and A. Jorres Interleukin-17: a mediator of inflammatory responses Cell Mol Life Sci 61 2004 567 579
44. M.I. Koenders, D. Isabel, R.J. Marijnissen, Shahla Abdollahi-Roodsaz, A.M.H. Boots, and B. Walgreen Interleukin-1 drives pathogenic Th17 cells during spontaneous arthritis in interleukin-1 receptor antagonist-deficient mice Arthritis Rheum 58 2008 3461 3470
45. E. Lubberts, L. Van den Bersselaar, B. Oppers-Walgreen, P. Schwarzenberger, C.J. Coenen-de Roo, and J.K. Kolls IL-17 promotes bone erosion in murine collagen-induced arthritis through loss of the receptor activator of NF-kappa B ligand/osteoprotegerin balance J Immunol 170 2003 2655 2662
46. E. Lubberts, M.I. Koenders, B. Oppers-Walgreen, L. Van den Bersselaar, C.J. Coenen-de Roo, and L.A. Joosten Treatment with a neutralizing anti-murine interleukin-17 antibo dy after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion Arthritis Rheum 50 2004 650 659
47. K. Zwerina, M. Koenders, A. Hueber, R.J. Marijnissen, W. Baum, and G.R. Heiland Anti IL-17A therapy inhibits bone loss in TNF-α-mediated murine arthritis by modulation of the T-cell balance Eur J Immunol 42 2 2012 413 423
48. S. Kotake, N. Udagawa, N. Takahashi, K. Matsuzaki, K. Itoh, and S. Ishiyama IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis J Clin Invest 103 1999 1345 1352
49. M. Chabaud, and P. Miossec The combination of tumor necrosis factor alpha blockade with interleukin-1 and interleukin-17 blockade is more effective for controlling synovial inflammation and bone resorption in an ex vivo model Arthritis Rheum 44 2001 1293 1303
50. U. Feige, Y.L. Hu, J. Gasser, G. Campagnuolo, L. Munyakazi, and B. Bolon Anti-interleukin-1 and anti-tumor necrosis factor-alpha synergistically inhibit adjuvant arthritis in Lewis rats Cell Mol Life Sci 57 2000 1457 1470
51. A.M. Bendele, E.S. Chlipala, J. Scherrer, J. Frazier, G. Sennello, and W.J. Rich Combination benefit of treatment with the cytokine inhibitors interleukin-1 receptor antagonist and PEGylated soluble tumor necrosis factor receptor type I in animal models of rheumatoid arthritis Arthritis Rheum 43 2000 2648 2659
52. J.H. Schwab, R.R. Brown, S.K. Anderle, and P.M. Schlievert Superantigen can reactivate bacterial cell wall-induced arthritis J Immunol 150 1993 4151 4159
53. J. Zwerina, S. Hayer, M. Tohidast-Akrad, H. Bergmeister, K. Redlich, and U. Feige Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: effects on synovial inflammation, bone erosion, and cartilage destruction Arthritis Rheum 50 2004 277 290
54. C. Plater-Zyberk, L.A. Joosten, M.M. Helsen, M.I. Koenders, P.A. Baeuerle, and W.B. van den Berg Combined blockade of granulocyte-macrophage colony stimulating factor and interleukin 17 pathways potently suppresses chronic destructive arthritis in a tumour necrosis factor alpha-independent mouse model Ann Rheum Dis 68 5 2009 721 728
55. M. Chabaud, F. Fossiez, J.L. Taupin, and P. Miossec IL-17 enhances the effects of IL-1 on IL-6 and leukemia inhibitory factor production by rheumatoid arthritis synoviocytes J Immunol 161 1998 409
56. L. Chen, D.Q. Li, J. Zhong, and X.L. Wu IL-17RA aptamer-mediated repression of IL-6 inhibits synovium inflammation in a murine model of osteoarthritis Osteoarthritis Cartilage 19 2011 711 718
57. P.F. Cheung, C.K. Wong, and C.W. Lam Molecular mechanisms of cytokine and chemokine release from eosinophils activated by IL-17A, IL-17F, and IL-23: implication for Th17 lymphocytesme diated allergic inflammation J Immunol 180 8 2008 5625 5635
58. L.K. Myers, E.F. Rosloniec, M.A. Cremer, and A.H. Kang Collagen induced arthritis, an animal model of autoimmunity Life Sci 61 1997 1861 1878
59. F.H. Durie, R.A. Fava, and R.J. Noelle Collagen-induced arthritis as a model of rheumatoid arthritis Clin Immunol Immunopathol 73 1994 11 18
60. L. Svensson, J. Jirholt, R. Holmdahl, and L. Jansson B cell-deficient mice do not develop type II collagen-induced arthritis (CIA) Clin Exp Immunol 111 1998 521 526
61. K. Terato, K.A. Hasty, R.A. Reife, M.A. Cremer, A.H. Kang, and J.M. Stuart Induction of arthritis with monoclonal antibodies to collagen J Immunol 148 1992 2103 2108